
    
      This is a Phase 2 study designed to evaluate the efficacy and safety of ABT-126 in
      approximately 410 adults with mild to moderate Alzheimer's disease. Subjects will be
      randomized to one of 5 treatment groups (ABT-126, donepezil or placebo) for a 24-week
      treatment period.
    
  